{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'due to presumed cardiac causes in a patient with or without pre-existing heart disease,', 'within 1 hour of the onset of acute symptoms or, in the case of an unwitnessed death,', 'within 24 hours after the patient was last seen alive and stable. If the cause of death is', 'unknown and cannot be ascertained at the time of reporting, \"unexplained death\" should', 'be recorded on the AE eCRF. If the cause of death later becomes available (e.g., after', 'autopsy), \"unexplained death\" should be replaced by the established cause of death.', '6.1.5', 'Adverse Event Collection Period', 'All adverse events reported from the time of blinded investigational product', 'administration until 70 days following the last dose of blinded investigational product will', 'be collected, whether solicited or spontaneously reported by the subject. In addition,', 'protocol-related serious adverse events and non-serious adverse events will be collected', 'from the time the subject signed the study-specific informed consent, only if considered', 'by the Investigator to be causally related to study-required procedures.', 'Adverse event information will be collected as shown in Figure 2.', 'Figure 2.', 'Adverse Event Collection', 'Protocol-Related SAEs', 'SAEs and Elicited and/or Spontaneously Reported', 'and Non-Serious AEs*', 'Non-Serious AEs', 'Consent', '5 Half Lives', 'Study Drug', 'Last Dose of', 'Signed', 'Start', 'Study Drug', '(70 days)', 'After Study', 'Drug Stopped', '*', 'Only if considered by the Investigator to be causally related to study-required procedures.', '81']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '6.1.6', 'Adverse Event Reporting', 'In the event of a serious adverse event, whether associated with blinded investigational', 'product or not, the Investigator will notify Clinical Pharmacovigilance within 24 hours of', 'the site being made aware of the serious adverse event by entering the serious adverse', 'event data into the electronic data capture (EDC) system. Serious adverse events that', 'occur prior to the site having access to the RAVE R system, or if RAVE is not operable,', 'should be documented on the SAE Non-CRF forms and emailed (preferred route) or faxed', 'to Clinical Pharmacovigilance within 24 hours of the site being made aware of the serious', 'adverse event.', 'Email:', 'FAX to:', 'For safety concerns, contact the Oncology Safety Management Team at:', 'Oncology Safety Team', 'AbbVie', '1 North Waukegan Road', 'North Chicago, IL 60064', 'Office:', 'Email:', '82']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'For any subject safety concerns, please contact the physician listed below:', 'Primary Therapeutic Area Medical Director:', 'Senior Medical Director', 'AbbVie', '1 North Waukegan Road', 'North Chicago, IL 60064', 'USA', 'Telephone Contact Information:', 'Office:', 'Mobile:', 'Email:', 'In emergency situations involving study subjects when the primary Therapeutic Area', 'Medical Director (TA MD) is not available by phone, please contact the 24-hour AbbVie', 'Medical Escalation Hotline where your call will be re-directed to a designated backup', 'AbbVie TA MD:', 'Phone:', 'AbbVie will be responsible for Suspected Unexpected Serious Adverse Reactions', '(SUSAR) reporting for the Investigational Medicinal Product (IMP) in accordance with', 'global and local guidelines and Appendix A of the Investigator Brochure will serve as the', 'Reference Safety Information (RSI). The RSI in effect at the start of a DSUR reporting', 'period serves as the RSI during the reporting period. For follow-up reports, the RSI in', \"place at the time of occurrence of the 'suspected' Serious Adverse Reaction will be used to\", 'assess expectedness.', 'In Japan, the principal investigator will provide documentation of all serious adverse', 'events to the Director of the investigative site and the Sponsor.', '83']\n\n###\n\n", "completion": "END"}